Compare Wynn Resorts, Limited (WYNN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wynn Resorts, Limited vs Zimmer Biomet Holdings Inc — how do they compare? Wynn Resorts, Limited trades at $75.15 (market cap $7.75B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.2× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Wynn Resorts, Limited for 76 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WYNN | ZBH | |
|---|---|---|
Market Cap | $7.75B | $16.95B |
Volume | 2,243,813 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.09 | $103.98 |
52-Week Low | $74.97 | $79.58 |
Typical Hold Time | 76 Days | 89 Days |
Enterprise Value | $17.99B | $24.02B |
Dividend Yield | 1.33% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wynn Resorts trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, but faces margin pressure in the U.S. and rising capital expenditure for new projects. Revenue for 2025 was $7.14 billion with a net income margin of 4.58%, while the balance sheet shows high long-term debt of $10.50 billion and negative shareholder equity.
The outlook is mixed: analyst consensus is bullish with a $132.36 price target, but risks include high leverage, project costs, and competitive pressures. Upside hinges on Macau recovery and successful project execution, while downside risks stem from debt servicing and macroeconomic volatility.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
